CGRP Antibodies as Prophylaxis in Migraine

Lars Edvinsson

doi:10.1016/j.cell.2018.11.049

CGRP Antibodies as Prophylaxis in Migraine

34 Citationer (Scopus)

Abstract

Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF.

Originalsprog	Engelsk
Tidsskrift	Cell
Vol/bind	175
Udgave nummer	7
Sider (fra-til)	1719
ISSN	0092-8674
DOI	https://doi.org/10.1016/j.cell.2018.11.049
Status	Udgivet - 2018
Udgivet eksternt	Ja

Adgang til dokumentet

10.1016/j.cell.2018.11.049

Citationsformater

@article{175b99bf5d6c49b99df68b35ec4c6bfe,

title = "CGRP Antibodies as Prophylaxis in Migraine",

abstract = "Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF.",

author = "Lars Edvinsson",

note = "Copyright {\textcopyright} 2018. Published by Elsevier Inc.",

year = "2018",

doi = "10.1016/j.cell.2018.11.049",

language = "English",

volume = "175",

pages = "1719",

journal = "Cell",

issn = "0092-8674",

publisher = "Cell Press",

number = "7",

}

TY - JOUR

T1 - CGRP Antibodies as Prophylaxis in Migraine

AU - Edvinsson, Lars

PY - 2018

Y1 - 2018

N2 - Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF.

AB - Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF.

U2 - 10.1016/j.cell.2018.11.049

DO - 10.1016/j.cell.2018.11.049

M3 - Journal article

C2 - 30550780

SN - 0092-8674

VL - 175

SP - 1719

JO - Cell

JF - Cell

IS - 7

ER -

CGRP Antibodies as Prophylaxis in Migraine

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater